

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate Cancer	ERG	Targeting the transcription factor ERG, which is mutated in more than 60% of prostate tumors, may be a strategy for treating prostate cancer. In cell culture and in mice, ERG overexpression was sufficient to transform prostate epithelial cells into invasive tumors. Transcriptional profiles of ERG-transformed cells revealed a number of changes in normal gene expression that may be responsible for the cancerous phenotype. Next steps include using a mouse with prostate-specific overexpression of ERG to study downstream target genes.	Not patented; unlicensed	Klezovitch, O. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Feb. 1, 2008; doi:10.1073/pnas.0711711105 Contact: Valeri Vasioukhin, Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Wash. e-mail: vvasiouk@fhcrc.org